| Species |
Human |
| Protein Construction |
CD300A (Leu18-Pro180)
Accession # Q9UGN4-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD300A, His, Human at 2μg/ml (100μl/Well) on the plate can bind AntiCD300A Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
18.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 48-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD300a is an inhibitory receptor for mast cells and eosinophils in allergic inflammation (AI); however, the spatiotemporal expression of CD300a and its potential roles in the resolution of AI are still to be determined.CD300a expression on peritoneal cells is regulated from inflammation to resolution. CD300a activation on mouse bone marrow-derived mast cells regulated ALX/FPR2 expression levels following IgE-mediated activation. |
| Synonyms |
IGSF12; IRp60; CLM-8; IRC1; CD300a; CLM8; LMIR1; MAIR-I; Mcipr1; NKRL; Pigr4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
